DNL343 is an investigational CNS penetrant eukaryotic initiation factor 2B activator that prevents and reverses the effects of neurodegeneration caused by the integrated stress response.

Saved in:

Bibliographic Details
Title:	DNL343 is an investigational CNS penetrant eukaryotic initiation factor 2B activator that prevents and reverses the effects of neurodegeneration caused by the integrated stress response.
Authors:	Yulyaningsih E; Denali Therapeutics, South San Francisco, United States., Suh JH; Denali Therapeutics, South San Francisco, United States., Fanok M; Denali Therapeutics, South San Francisco, United States., Chau R; Denali Therapeutics, South San Francisco, United States., Solanoy H; Denali Therapeutics, South San Francisco, United States., Takahashi R; Denali Therapeutics, South San Francisco, United States., Bakardjiev AI; Denali Therapeutics, South San Francisco, United States., Becerra I; Denali Therapeutics, South San Francisco, United States., Benitez NB; Denali Therapeutics, South San Francisco, United States., Chiu CL; Denali Therapeutics, South San Francisco, United States., Davis SS; Denali Therapeutics, South San Francisco, United States., Dowdle WE; Denali Therapeutics, South San Francisco, United States., Earr T; Denali Therapeutics, South San Francisco, United States., Estrada AA; Denali Therapeutics, South San Francisco, United States., Gill A; Denali Therapeutics, South San Francisco, United States., Ha C; Denali Therapeutics, South San Francisco, United States., Haddick PCG; Denali Therapeutics, South San Francisco, United States., Henne KR; Denali Therapeutics, South San Francisco, United States., Larhammar M; Denali Therapeutics, South San Francisco, United States., Leung AW; Denali Therapeutics, South San Francisco, United States., Maciuca R; Denali Therapeutics, South San Francisco, United States., Memarzadeh B; Denali Therapeutics, South San Francisco, United States., Nguyen HN; Denali Therapeutics, South San Francisco, United States., Nugent AA; Denali Therapeutics, South San Francisco, United States., Osipov M; Denali Therapeutics, South San Francisco, United States., Ran Y; Denali Therapeutics, South San Francisco, United States., Rebadulla K; Denali Therapeutics, South San Francisco, United States., Roche E; Denali Therapeutics, South San Francisco, United States., Sandmann T; Denali Therapeutics, South San Francisco, United States., Wang J; Denali Therapeutics, South San Francisco, United States., Lewcock JW; Denali Therapeutics, South San Francisco, United States., Scearce-Levie K; Denali Therapeutics, South San Francisco, United States., Kane LA; Denali Therapeutics, South San Francisco, United States., Sanchez PE; Denali Therapeutics, South San Francisco, United States.
Source:	ELife [Elife] 2024 Sep 17; Vol. 12. Date of Electronic Publication: 2024 Sep 17.
Publication Type:	Journal Article
Journal Info:	Publisher: eLife Sciences Publications, Ltd Country of Publication: England NLM ID: 101579614 Publication Model: Electronic Cited Medium: Internet ISSN: 2050-084X (Electronic) Linking ISSN: 2050084X NLM ISO Abbreviation: Elife Subsets: MEDLINE
Database:	MEDLINE Ultimate

Description
ISSN:	2050-084X
DOI:	10.7554/eLife.92173